The Samuel Waxman Cancer Research Foundation is an international organization dedicated to curing and preventing cancer. The Foundation is a pioneer in cancer research, focusing on uncovering the causes of cancer and reprogramming cancer cells. We dedicate ourselves to delivering tailored, minimally toxic treatments to patients. Our mission is to eradicate cancer by bridging the gap between lab science and the patient. Through our collaborative group of world-class scientists, the Institute Without Walls, investigators share information and tools to speed the pace of cancer research. Since our inception in 1976, the Foundation has awarded more than $75 million to support the work of more than 175 researchers across the globe.
For 35 years, the Samuel Waxman Cancer Research Foundation has been a pioneer in tackling cancer at its root and reprogramming cancer cells. Our mission is twofold: to deliver less toxic treatments and to bring faster cures to patients. Enhancing the quality of life for cancer survivors is an important part of the research that we fund, which is why our scientists are looking at the biology of the disease and investigating ways to stop cancer from spreading.

Although current treatment options like chemotherapy and radiation are effective against some cancers, they are not effective against all cancers. Indeed, the harsh treatment options today can leave many survivors with long-term survivorship issues. The Waxman Foundation believes there must be a better way.

Our funded investigators include some of the best scientific minds in cancer research. We support ongoing multi-disciplinary innovative research projects by highly-respected teams of scientists who like to think out-of-the-box in solving a problem. Because their proposals are often considered “high risk” by institutions like the National Cancer Institute, these brilliant researchers might not receive funding for their new approaches to kill cancer cells.

The good news is that the Waxman Foundation has taken risks to invest in these researchers, many of whom have gone on to leverage their initial Waxman seed grant to secure millions of dollars from the National Cancer Institute—which deemed their projects too risky in the first place. Ironic? Perhaps. But this is the unique niche that the Foundation fulfills in cancer research. We’ve been doing it for 35 years and are very proud of what we have been able to accomplish together with your help. Thank you for joining with us as we envision a world without cancer.
JULY 1, 2010 The SWCRF awards more than $2 million as part of its science grant program.

AUG. 14, 2010 The 7th Annual Hamptons Happening raises more than $250,000.

SEPT. 14, 2010 Marcia and David Laviour host a cocktail party with their niece Jennifer Schwab Yanowitz to launch a donor-directed grant in chronic myeloid leukemia.

NOV. 7, 2010 Eleven runners from Team Waxman participate in the ING New York City Marathon and raise more than $94,000.

NOV. 18, 2010 The 13th Annual Collaborating for a Cure Gala raises nearly $3.4 million.

JAN. 1, 2011 The SWCRF invites cancer centers across the U.S. to apply for research grants.

JAN. 27, 2011 The Max Cure Foundation partners with the Waxman Foundation to sponsor a grant in pediatric cancer research.

APRIL 1, 2011 Deadline to submit grant proposals.

APRIL 8, 2011 The Millennial Society raises $92,000 at its annual Spring for a Cure benefit.


MAY 16, 2011 Donors, board members and stakeholders attend the Annual Scientific Symposium, which also featured Donor Recognition awards.

JUNE 20, 2011 The 29th Annual Golf Tournament & Dinner at the Creek Club, in Locust Valley, N.Y., raises more than $130,000.

JUNE 24, 2011 The 2011–2012 SWCRF grant recipients are notified of their awards, which included individual and collaborative grants.
YOUR INVESTMENT IN CANCER RESEARCH

Supporting cancer research is a long-term investment. For scientists, it takes years, even decades (if they’re lucky) to see any fruition from the intense labor they pour into their research. The same can be said of donors who commit generous dollars to support the work.

How can donors be certain that their gifts to the Waxman Foundation are making a contribution toward innovative science? One way is the impact that our researchers are making in the cancer community. Some of the scientists who are funded by the SWCRF are cited five to six times more than the average scientist in top scientific journals. What does that mean? The SWCRF is wisely investing donor dollars to scientists who are furthering scientific advances.

We have been able to support the work of NIH-funded scientists who are taking new approaches in reprogramming cancer cells and, developing epigenetic therapies that have the potential to translate into minimally toxic treatments for patients.

Thank you for your dedication and commitment to the Foundation. To show you where your money goes, we have included a brief explanation of your long-term investment in cancer research.

INDIVIDUAL GRANTS

Individual grants from the Foundation are awarded to investigators who study potential novel therapies and conduct basic and translational research in reprogramming cancer cells. In the past, many individual grant recipients have gone on to apply for and receive collaborative grants from the Foundation. In July 2011, the Foundation continued to support the research of the three individual grant recipients from last year, and also added six additional grantees.

MOUNT SINAI MEDICAL CENTER

Since 1976, the Foundation has supported researchers at the SWCRF laboratory in Mount Sinai Medical Center to study gene expression, tumor dormancy, breast cancer research, and hematologic research. Scientists at the Waxman lab have made breakthroughs over the years, including working with Chinese researchers to develop a less toxic therapy to cure acute promyelocytic leukemia (APL) as well as developing a small molecule inhibitor to target a deadly breast cancer known as triple-negative breast cancer.

SHANGHAI INSTITUTE OF HEMATOLOGY IN CHINA

The Samuel Waxman Cancer Research Foundation was one of the first cancer research foundations to partner with researchers in China in the 1980s. The long-standing collaboration with researchers at the Shanghai Institute of Hematology (SIH) has led to a number of advances in cancer research, including the development of a less toxic therapy to cure APL. Continued support from the Emerald Foundation, Inc. and the Rose M. Badgeley Charitable Trust is helping scientists at the SIH conduct ongoing research to eradicate the leukemia stem cell.

COLLABORATIVE GRANTS

Collaborative grants are awarded to investigators to form ongoing multi-disciplinary teams to move science from the bench to the clinic. In the past, many collaborative grant recipients have gone on to leverage their SWCRF seed grant and apply for and receive additional funding from the National Cancer Institute. In July 2011, the Foundation awarded 18 collaborative grants to researchers around the world studying differentiation therapy, epigenetics and cancer stem cells.
WHERE YOUR MONEY GOES

COLLABORATIVE GRANTS
55%

INDIVIDUAL GRANTS
26%

SWCRF LAB AT MOUNT SINAI
15%

SHANGHAI INSTITUTE OF HEMATOLOGY IN CHINA
4%

ALLOCATION OF RESEARCH FUNDS ($3.7 MILLION) 2011–2012

WHEEATATION OF RESEARCH FUNDS ($3.7 MILLION) 2011–2012

WHEEATATION OF RESEARCH FUNDS ($3.7 MILLION) 2011–2012

WHEEATATION OF RESEARCH FUNDS ($3.7 MILLION) 2011–2012

WHEEATATION OF RESEARCH FUNDS ($3.7 MILLION) 2011–2012
Collaborating for a Cure

Ron Evans, Reuben Shaw are studying the molecular mechanisms and the role of inflammation on diet-induced intestinal cancer.

Reuben Shaw, Ruben Shw are studying the molecular mechanisms and the role of inflammation on diet-induced intestinal cancer.

William Weiss, Kevan ShoKat, Mark Lemmon, Albert Baldwin Jr. are studying a family of proteins in a deadly form of brain cancer.

Alan Friedman, Albert Baldwin Jr. are investigating programmed cell death in cancer by targeting proteins.

Ethan Dmitrovsky, Yolanda Sanchez, Duane Compton are collaborating on targeted lung cancer therapies.

Ethan Dmitrovsky, Jonathan Licht are collaborating on PLZF in lung cancer.

Ron Evans, Reuben Shaw are studying oncoproteins in blood cancers.

Samuel Waxman, Doris Germain are studying oncoproteins in blood cancers.

Samuel Waxman, Doris Germain are collaborating on a novel therapy in breast cancer research.

Wilson Miller, Jonathan Licht are collaborating on a novel therapy in breast cancer research.

Samuel Waxman Cancer Research Foundation
The Samuel Waxman Cancer Research Foundation believes collaboration drives innovation and brings faster cures to patients. These are some of the ways that members of our Institute Without Walls are working together to make breakthroughs in cancer research.

**Arthur Zelent, Frank Rauscher III**
- are targeting the Snail Machinery that controls the EMT differentiation program during metastasis.

**John Crispino, Shai Izraeli**
- are investigating the link between Down Syndrome and a form of leukemia.

**Arthur Zelent, Ming-Ming Zhou**
- are developing a protein-inhibitor for targeted epigenetic cancer therapy.

**John Crispino, Samuel Waxman**
- are collaborating on triple-negative breast cancer.

**Robert A. Weinberg**
- is studying breast cancer stem cells.

**Anthony Capobianco, Alexander Mackerell**
- are exploiting the Notch Pathway to develop novel anti-cancer therapeutics.

**Shanghai Institute of Hematology, Samuel Waxman, Arthur Zelent, Jonathan Licht**
- are collaborating with researchers in China to develop new therapies for leukemia.

**Samuel Waxman, Alan Ashworth**
- are collaborating on triple-negative breast cancer.

**Ari Melnick, Wilson Miller**
- are collaborating with researchers at the SIH to eradicate the leukemia stem cell.

**Ari Melnick, Alexander Mackerell, Gilbert Prive**
- are targeting oncogenic transcriptional repressor proteins in B-cell lymphoma.
Cancer is not one disease. Hundreds of types of cancer exist, if not more. And so our scientists are studying the biology of cancer to tackle the disease at its root. They are analyzing how different genes and enzymes affect cancer’s growth.

Which is why, “when our Scientific Advisory Board evaluates and recommends research grants for funding, they do so keeping in mind the big picture, and how each grant will support and add to the Foundation's body of work,” explained Jonathan Licht, M.D., an Associate Scientific Director of the SWCRF.

“At times, people don’t understand what we do because the Waxman Foundation is not driven to fund research in one type of cancer,” said Gwen Darien, the Foundation’s Executive Director. “It’s not that we don’t support research in specific programs, because we do fund research in breast cancer, brain cancer, colon cancer, leukemias, lung cancer, and pancreatic cancer. But the overlapping theme of funded projects must align with our mission to reprogram cancer cells.”

How is the Waxman Foundation furthering cancer research? By fostering collaboration between scientists across geographical borders and across multiple disciplines.

“Grants only receive additional funding for subsequent years if scientists have demonstrated that they collaborated with other members of the Institute Without Walls,” explained Samuel Waxman, M.D., the Founder and Scientific Director of the SWCRF. “Our definition of collaboration is not merely sharing cell lines and mouse models. We have molecular biologists working together with structural chemists and oncologists to identify novel therapies and new targets.”

Not only that, but much of the research that Waxman-funded investigators are working on has the potential to be applied in other types of cancer because they are looking at enzymes, tumor markers and pathways that cross over into different types of leukemia and in some cases, even solid tumors.

When cancer develops, it’s because the built-in instructions within cells to differentiate are not followed, explained Waxman. Scientists funded by the Waxman Foundation are trying to reverse that process, whether it’s by flipping a genetic switch to reprogram that cancer cell to stop growing or by designing small molecules that block that message from being sent.

“The scientific process is laborious and often met with frustration when experiments don’t lead to immediate success,” said Ethan Dmitrovsky, M.D., who is an Associate Scientific Director of the SWCRF. “But the Waxman Foundation is committed to translating basic research to the cancer community and bringing faster cures to patients. Indeed, the Foundation is uniquely situated to bridging this gap between bench and bedside.”

The nimble nature of the Foundation to identify and to fund research projects that have the high potential for important gains in cancer research is what sets it apart, said Darien. “I can honestly say that we support cutting-edge research by some of the best scientists in the world.”

“The future of making progress in cancer research lies in members of the cancer community coming together to find cures across all disease types,” said Waxman. “This is the vision behind what we do, which I believe is the most effective way to bringing about a world without cancer.”
TUMOR DORMANCY
LIVER CANCER
PANCREATIC CANCER
BREAST CANCER
CHILDHOOD AND YOUNG ADULT CANCERS
BRAIN CANCER
OVARIAN CANCER
BLOOD MALIGNANCIES
DEVELOPING EPIGENETIC THERAPY

BRAIN CANCER PROGRAM
Albert S. Baldwin, Jr., Ph.D., University of North Carolina, Chapel Hill
Mark Lemmon, Ph.D., University of Pennsylvania
Kevan Shokat, Ph.D., University of California, San Francisco
William Weiss, M.D., Ph.D., University of California, San Francisco

COLON CANCER PROGRAM
Ronald M. Evans, Ph.D., Salk Institute
Reuben Shaw, Ph.D., Salk Institute

LIVER CANCER PROGRAM
Stephen Baylin, M.D., Johns Hopkins University
Paul B. Fisher, M.Ph., Ph.D., Virginia Commonwealth University
Josep M. Llovet, M.D., Mount Sinai Medical Center
Devanand Sarkar, M.B.B.S., Ph.D., Virginia Commonwealth University
Samuel Waxman, M.D., Mount Sinai Medical Center

PANCREATIC CANCER PROGRAM
Nabeel Bardessy, Ph.D., Massachusetts General Hospital
Paul B. Fisher, M.Ph., Ph.D., Virginia Commonwealth University

CANCER STEM CELL PROGRAM
Julio Aguirre-Ghiso, Ph.D., Mount Sinai Medical Center
Nabeel Bardeesy, Ph.D., Massachusetts General Hospital
Stephen Baylin, M.D., Johns Hopkins University
Ravi Bhatia, M.D., City of Hope
Robert A. Casero, Ph.D., Johns Hopkins University
Margaret Goodell, Ph.D., Baylor College of Medicine
Benjamin G. Neel, M.D., Ph.D., Ontario Cancer Institute
Yolanda Sanchez, Ph.D., Dartmouth School of Medicine
Robert A. Weinberg, Ph.D., Whitehead Institute for Biomedical Research
Cynthia Zahnow, Ph.D., Johns Hopkins University

MOUNT SINAI MEDICAL CENTER SWCRF LABORATORY
Julio Aguirre-Ghiso, Ph.D., Mount Sinai Medical Center
Eduardo Farias, Ph.D., Mount Sinai Medical Center
Doris Germain, Ph.D., Mount Sinai Medical Center
Yongkui Jing, Ph.D., Mount Sinai Medical Center
Boris Leibovitch, Ph.D., Mount Sinai Medical Center
Samuel Waxman, M.D., Mount Sinai Medical Center

MELANOMA PROGRAM
Paul B. Fisher, M.Ph., Ph.D., Virginia Commonwealth University
Neal Rosen, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center

OVARIAN CANCER
Benjamin G. Neel, M.D., Ph.D., Ontario Cancer Institute
Garry P. Nolan, Ph.D., Stanford University School of Medicine

BREAST CANCER PROGRAM
Alan Ashworth, Ph.D., Institute of Cancer Research
Albert S. Baldwin, Jr., Ph.D., University of North Carolina, Chapel Hill
Stephen Baylin, M.D., Johns Hopkins University
Robert A. Casero, Ph.D., Johns Hopkins University
Eduardo Farias, Ph.D., Mount Sinai Medical Center
Doris Germain, Ph.D., Mount Sinai Medical Center
Wilson Miller, M.D., Ph.D., Jewish General Hospital
Samuel Waxman, M.D., Mount Sinai Medical Center
Robert A. Weinberg, Ph.D., Whitehead Institute for Biomedical Research
Cynthia Zahnow, Ph.D., Johns Hopkins University
Arthur Zelent, Ph.D., Institute of Cancer Research
Ming-Ming Zhou, Ph.D., Mount Sinai School of Medicine

LUNG CANCER PROGRAM
Duane Compton, Ph.D., Dartmouth Medical School
Ethan Dmitrovsky, M.D., Dartmouth Medical School
Gerard Evan, Ph.D., University of California, San Francisco
Yolanda Sanchez, Ph.D., Dartmouth Medical School
Jeffrey Settleman, Ph.D., Genentech
Tumor Dormancy Program
Julio Aguirre-Ghiso, Ph.D., Mount Sinai Medical Center
Eduardo Farias, Ph.D., Mount Sinai Medical Center

Childhood and Young Adult Cancers
Albert Baldwin, Jr., Ph.D., University of North Carolina, Chapel Hill
James E. Bradner, M.D., Dana-Farber Cancer Institute
Anthony Capobianco, Ph.D., University of Miami
John D. Crispino, Ph.D., Northwestern University
Alan Friedman, M.D., Johns Hopkins University
Christopher A. French, M.D., Brigham and Women’s Hospital
Shai Izraeli, M.D., Tel Aviv University
Scott Hiebert, Ph.D., Vanderbilt University
Mark Lemmon, Ph.D., University of Pennsylvania
Kevan Shokat, Ph.D., University of California, San Francisco
Erwin G. Van Meir, Ph.D., Emory University School of Medicine
William Weiss, M.D., Ph.D., University of California, San Francisco

SIV/SWCRF Co-PI Program
Sai-Juan Chen, M.D., Ph.D. Shanghai Institute of Hematology
Zhu Chen, M.D., Ph.D. Shanghai Institute of Hematology

Developing Epigenetic Therapy
Stephen Baylin, M.D., Johns Hopkins University
Anthony Capobianco, Ph.D., University of Miami
Robert A. Casero, Ph.D., Johns Hopkins University
Sai-Juan Chen, Ph.D., Shanghai Institute of Hematology
John D. Crispino, M.D., Northwestern University
Ronald M. Evans, Ph.D., Salk Institute
Alan Friedman, M.D., Johns Hopkins University
Margaret Goodell, Ph.D., Baylor College of Medicine
Scott Hiebert, Ph.D., Vanderbilt University
Shai Izraeli, M.D., Tel Aviv University
Yongkui Jing, Ph.D., Mount Sinai Medical Center
Craig T. Jordan, Ph.D., University of Rochester
Jonathan D. Licht, M.D., Northwestern University
Alexander MacKerell, Ph.D., University of Maryland
Ari Melnick, M.D., Weill Cornell School of Medicine
Wilson Miller, M.D., Ph.D., Jewish General Hospital
Kevin Petrie, Ph.D., Institute of Cancer Research
Gilbert Privé, Ph.D., University of Toronto
Frank J. Rauscher III, Ph.D., Wistar Institute
Ruibao Ren, M.D., Ph.D., Brandeis University
Samuel Waxman, M.D., Mount Sinai Medical Center
Yue Xiong, Ph.D., University of North Carolina, Chapel Hill
Arthur Zelent, Ph.D., Institute of Cancer Research, London
Ming-Ming Zhou, Ph.D., Mount Sinai School of Medicine

Blood Malignancies
Ravi Bhatia, M.D., City of Hope
Anthony Capobianco, Ph.D., University of Miami
Sai-Juan Chen, M.D., Ph.D., Shanghai Institute of Hematology
John Crispino, Ph.D., Northwestern University
Alan Friedman, M.D., Johns Hopkins University
Margaret Goodell, Ph.D., Baylor College of Medicine
Scott Hiebert, Ph.D., Vanderbilt University
Yongkui Jing, Ph.D., Mount Sinai School of Medicine
Craig T. Jordan, Ph.D., University of Rochester
Jonathan D. Licht, M.D., Northwestern University
Ari Melnick, M.D., Weill Cornell Medical Center
Warren Pear, M.D., Ph.D., University of Pennsylvania
Ruibao Ren, M.D., Ph.D., Brandeis University
Erwin G. Van Meir, Ph.D., Emory University School of Medicine
Samuel Waxman, M.D., Mount Sinai School of Medicine
Arthur Zelent, Ph.D., Institute of Cancer Research
When you invest in cancer research, you are investing in the future—not just your own future, but the future of your children, your grandchildren and generations to come. Every dollar you give to the Waxman Foundation helps us bring about such a future, that is, a world without cancer.

At times it’s hard for us to imagine that future when we lose loved ones to the disease. But please know that your generous donations and commitment to the Foundation are helping to make great strides in cancer research as scientists uncover more about the disease; investigating ways to reprogram and kill cancer cells.

It’s amazing how far we have come in expanding our knowledge about cancer and developing effective therapies. The Waxman Foundation has played an important role in this effort for 35 years. We thank you for your continued support in our endeavor.

—Gary Jacob
Development Chair
IN HONOR OF/IN MEMORY OF

Mary L. Bendik
Donald Bleyman
Lois Cherry
George Harrell Childs
Sydelle Chusid
Peter Claman
Cris Cleland
Pat DiPrete Antonio
Elliot and Karen Fishkin
Elliot and Barbara Fishkin
Mark J. Fizulich
James E. Frankel
Nancy Gilbert
Gary Gladstein
Judith Gladstein
Manisha L. Gladstein
Stephen Glazer
Jay M. Green
Clifford and Alyssa Greenberg
Carol Grubman
Sara Hansen
Scott Hansen
Wilma Hurst
Richard Jackson
Alissa Jacob
Gary Jacob
Linda Jacob
Shirley Kivlan
Dorris Konzer
Michael Lani
David and Marcia Lavipour
Jessica A. Levin
Abner and Mildred Levine
Slebano Loffredo
Keith Lombardo
Camilla R. Marcus Siegel
James Massaia
John Massaia
Keith Lombardo
J York Sokol
alma b. Simmons
edwin C. Scheurer
Julie Poza
Elizabeth Pastorech
James Rapaport
Charles and Laurie Schafflen
Edwin C. Scheurer
Arnold Schwartz, M.D.
Alma B. Simmon
Howard Simon
Jordan Sokol
Michael Sokol
Jenny Song
Martin and Aly St. Pierre
Charles Wantman
Alex Waerman
Samuel Waxman
John Weed
Saul Weinberger
Leonard Weinstein
Fern Weiss
Theresa Wells
David D. Welti
David Workman

A NOTE TO OUR SUPPORTERS

We have carefully reviewed all gifts made to the Samuel Waxman Cancer Research Foundation to ensure each gift is properly recognized. Gifts mentioned exclude in-kind donations. The Thank You list includes gifts made between July 1, 2010 and June 30, 2011.

Occasionally, despite our best efforts, errors do occur. If we have made mistakes, we sincerely apologize in advance. You can alert us of such errors by contacting our office at 212.867.4502.

Please note that we make every effort to follow the donor’s preferences when compiling the annual report list. If you would prefer to have your name listed differently in the future, please let us know.
# FINANCIAL STATEMENT

(Undaunted) July 1, 2010–June 30, 2011

<table>
<thead>
<tr>
<th>Revenue</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>550,000</td>
</tr>
<tr>
<td>Program Grants</td>
<td>1,080,000</td>
</tr>
<tr>
<td>Fundraising Income (Net of Expense)</td>
<td>1,891,000</td>
</tr>
<tr>
<td>Investment Income</td>
<td>175,000</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td><strong>$3,696,000</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expense</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td>$2,897,000</td>
</tr>
<tr>
<td>Fundraising</td>
<td>250,000</td>
</tr>
<tr>
<td>Management and General</td>
<td>720,000</td>
</tr>
<tr>
<td><strong>Total Expense</strong></td>
<td><strong>$3,867,000</strong></td>
</tr>
</tbody>
</table>

| Surplus/(Deficit)                           | ($171,000)|
| Net Assets                                  | $6,452,000|
SAMUEL WAXMAN
CANCER RESEARCH FOUNDATION

CHAIRMAN
Michael Nierenberg

VICE PRESIDENTS
Gary Jacob, J.Jay Mautner, David S. Taub, Dena K. Weiner

SECRETARY
Laurie L. Schaffran

TREASURER
Thomas A. Conway

BOARD OF DIRECTORS
David B. Benham, Dale Claman, James E. Frankel,
Gary Gladstein, Clifford Greenberg, Dennis A. Herman, Linda Herman, Alissa Jacob,
Costas Kondylis, Abner Levine, Mildred Levine,
Camilla Marcus Siegel, Musa Mayer, Howard Shlaifmizt, Tony M. Shogren,
Clifford Sterling, Samuel Waxman, M.D., Spencer Waxman

FOUNDER AND SCIENTIFIC DIRECTOR
Samuel Waxman, M.D.

EXECUTIVE DIRECTOR
Gwen Darien

HONORARY BOARD
Maureen Cogan
Martin L. Coyne
Mary Kantor
Susan W. Rose
Alan P. Safir*
Joan A. Safir*
Alfred J. Seaman*
Zena Wiener
* Past Chair

CHAIRMAN’S COUNCIL
Lawrence Altman
Peter Claman
Robert E. Fischer
Arminio Fraga
Thomas Marano
Richard Mazer
Edward Sheldon
Bernard Sillins

ASSOCIATE SCIENTIFIC DIRECTORS
Ethan Dmitrovsky, M.D.
Jonathan Licht, M.D.

SCIENTIFIC ADVISORY BOARD
Steven J. Burakoff, M.D.
Riccardo Dalla-Favera, M.D.
Lorraine Gudas, Ph.D.
Alan Rosmarin, M.D.
Nancy Speck, Ph.D.
Hua Yu, Ph.D.

MILLENNIAL SOCIETY EXECUTIVE COMMITTEE
Alissa Jacob
Ethel Cohen
Kylie Davis
Camilla Marcus Siegel
Lauren Moise
Bryan Rodman
Jake Sokol

FOUNDATION STAFF
Amanda Aronson
Carole Asher
Jay Camp
Michelle A. Nicholas
Jenny Song
Bridget Stein

ANNUAL REPORT DESIGN
Yolanda Cuomo, NYC